PCM
ALXN

Proxima Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Proxima Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,000
Closed -$1.82M – 39
2017
Q2 		$1.82M Hold
15,000
– – 0.99% 28
2017
Q1 		$1.82M Hold
15,000
– – 1.11% 27
2016
Q4 		$1.83M Buy
+15,000
New +$1.84M 0.92% 26

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Proxima Capital Management's ALXN Position: Q3 2017 in Review

Proxima Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 15,000 shares — an estimated $1.82M sold.

Proxima Capital Management first reported a position in ALXN in Q4 2016 and held it in 3 quarters. The position peaked at $1.83M in Q4 2016. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Proxima Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Proxima Capital Management sold 15,000 Alexion Pharmaceuticals shares in Q3 2017, an estimated $1.82M.
  • Proxima Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Proxima Capital Management's Alexion Pharmaceuticals position peaked at $1.83M in Q4 2016.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Proxima Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.